Detection of Lipitor counterfeits: a comparison of NIR and Raman spectroscopy in combination with chemometrics.
Research has been carried on the feasibility of near infrared (NIR) and Raman spectroscopy as rapid screening methods to discriminate between genuine and counterfeits of the cholesterol-lowering medicine Lipitor. Classification, based on partial least squares discriminant analysis (PLS-DA) models, appears to be successful for both spectroscopic techniques, irrespective of whether atorvastatine or lovastatine has been used as the active pharmaceutical ingredient (API). The discriminative power of the NIR model, in particular, largely relies on the spectral differences of the tablet matrix. This is due to the relative large sample volume that is probed with NIR and the strong spectroscopic activity of the excipients. PLS-DA models based on NIR or Raman spectra can also be applied to distinguish between atorvastatine and lovastatine as the API used in the counterfeits tested in this study. A disadvantage of Raman microscopy for this type of analysis is that it is primarily a surface technique. As a consequence spectra of the coating and the tablet core might differ. Besides, spectra may change with the position of the laser in case the sample is inhomogeneous. However, the robustness of the PLS-DA models turned out to be sufficiently large to allow a reliable discrimination. Principal component analysis (PCA) of the spectra revealed that the conditions, at which tablets have been stored, affect the NIR data. This effect is attributed to the adsorption of water from the atmosphere after unpacking from the blister. It implies that storage conditions should be taken into account when the NIR technique is used for discriminating purposes. However, in this study both models based on NIR spectra and Raman data enabled reliable discrimination between genuine and counterfeited Lipitor tablets, regardless of their storage conditions.
de Peinder
P
P
VibSpec, Haaftenlaan 28, 4006 XL Tiel, The Netherlands. info@vibspec.com
Vredenbregt
M J
MJ
Visser
T
T
de Kaste
D
D
D000924:Anticholesteremic Agents / Q000032:analysis* / Q000737:chemistry; D000069059:Atorvastatin; D004304:Dosage Forms / Q000592:standards; D004356:Drug Storage; D005079:Excipients / Q000737:chemistry / Q000592:standards; D006538:Heptanoic Acids / Q000032:analysis* / Q000737:chemistry; D016018:Least-Squares Analysis; D015394:Molecular Structure; D025341:Principal Component Analysis; D011758:Pyrroles / Q000032:analysis* / Q000737:chemistry; D019265:Spectroscopy, Near-Infrared / Q000592:standards; D013059:Spectrum Analysis, Raman / Q000592:standards; D013607:Tablets / Q000737:chemistry / Q000592:standards; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000592:standards
D000924:Anticholesteremic Agents; D004304:Dosage Forms; D005079:Excipients; D006538:Heptanoic Acids; D011758:Pyrroles; D013607:Tablets; D000069059:Atorvastatin